founder
Dr. Osborne is a physician–scientist and translational leader in molecular imaging and radioligand theranostics, advancing precision oncology through innovation and strategic program development. He serves as Chief of Molecular Imaging & Therapeutics and Director of the Radioligand Laboratory at Weill Cornell Medicine, where he leads multidisciplinary teams developing next-generation imaging and theranostic platforms with clinical and commercial relevance. Trained at Columbia University (MD/PhD under Nobel Laureate Richard Axel), he previously held senior leadership roles at Memorial Sloan Kettering Cancer Center. Dr. Osborne has authored more than 100 peer-reviewed publications, led pioneering clinical trials, and brings a board- and advisory-ready perspective focused on translation, scalability, and access.
Manuel A. Paris | Co-Founder, MI4
Manuel A. Paris is a transformational healthcare executive with more than two decades of progressive leadership experience across academic medical centers, integrated health systems, and cancer centers, including leadership roles at Memorial Sloan Kettering Cancer Center, NewYork-Presbyterian, and the University of Florida College of Medicine–Jacksonville. His expertise spans enterprise strategy, financial and operational leadership, regional expansion, and the development of advanced imaging, molecular medicine, and oncology-aligned programs. Recognized for driving organizational transformation, aligning multidisciplinary teams, and scaling complex clinical enterprises, he brings a strategic perspective that connects innovation with operational execution. As Co-Founder of MI4, Mr. Paris focuses on advancing molecular imaging and theranostics through sustainable growth strategies, strategic partnerships, and innovative healthcare delivery models that strengthen access, performance, and patient-centered care.
